rofecoxib and Ache
rofecoxib has been researched along with Ache in 76 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The preoperative administration of rofecoxib was not effective in reducing pain in uterine curettage." | 9.11 | Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. ( Phupong, V; Poomtavorn, Y, 2005) |
| "5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)." | 9.11 | Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004) |
| "In this double-blind, randomized, two-phase study, patients with moderate to severe pain after surgical extraction of >or= 2 third molars, including one mandibular impaction, were treated with rofecoxib 50 mg, oxycodone/acetaminophen 10/650 mg (singledose phase) followed by 5/325 mg every 6h as needed (multidose phase), or placebo." | 9.11 | Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. ( Bird, SR; Black, P; Chang, DJ; Chen, E; Desjardins, PJ; Geba, GP; Petruschke, RA, 2004) |
| "We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain." | 9.11 | Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers. ( Fuller, A; Loram, LC; Mitchell, D, 2005) |
| "An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment." | 9.10 | Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 9.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| "Rofecoxib effectively treated primary dysmenorrhea, and cyclooxygenase-2-derived prostanoids play a role in the pathophysiology of primary dysmenorrhea." | 9.09 | Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. ( Cantu, N; Daniels, SE; Kotey, P; Morrison, BW; Seidenberg, B, 1999) |
| " In the dental pain study, total pain relief (TOTPAR) over the 6 hours after dosing was similar between 50 mg and 500 mg rofecoxib and 400 mg ibuprofen (P > ." | 9.09 | Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. ( Dallob, A; De Lepeleire, I; De Schepper, P; Ehrich, EW; Gertz, BJ; Mehlisch, DR; Porras, A; Riendeau, D; Seibold, JR; Van Hecken, A; Wittreich, J; Yuan, W, 1999) |
| "To assess the efficiency of paracetamol, indicated in first instance for light-to-moderate pain from hip and knee arthrosis, against rofecoxib, the COX-2 inhibitor most commonly used in Spain." | 8.82 | [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. ( Lizán Tudela, L; Magaz Marqués, S; Riesgo Bucher, Y; Varela Moreno, C, 2004) |
| "To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement." | 7.71 | Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. ( Bolognese, J; Detora, LM; Ehrich, EW; Krupa, D; Sperling, RS, 2001) |
| "Pretreatment with Rofecoxib significantly reduced post-SWL pain from 5." | 6.74 | Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib. ( Erturk, E; Greene, TD; Joseph, JV, 2009) |
| "Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment." | 6.73 | Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. ( Dionne, RA; Hamza, M; Ramsay, ES; Wahl, SM; Wang, XM; Wu, TX, 2007) |
| "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day." | 6.41 | Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001) |
| "Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis." | 5.32 | [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003) |
| "We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain." | 5.11 | Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers. ( Fuller, A; Loram, LC; Mitchell, D, 2005) |
| "5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)." | 5.11 | Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004) |
| "The preoperative administration of rofecoxib was not effective in reducing pain in uterine curettage." | 5.11 | Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. ( Phupong, V; Poomtavorn, Y, 2005) |
| "In this double-blind, randomized, two-phase study, patients with moderate to severe pain after surgical extraction of >or= 2 third molars, including one mandibular impaction, were treated with rofecoxib 50 mg, oxycodone/acetaminophen 10/650 mg (singledose phase) followed by 5/325 mg every 6h as needed (multidose phase), or placebo." | 5.11 | Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. ( Bird, SR; Black, P; Chang, DJ; Chen, E; Desjardins, PJ; Geba, GP; Petruschke, RA, 2004) |
| "Patient overall pain assessment, and patient and investigator global assessments were each measured on a 100mm VAS and on a 0 to 4 point Likert scale in a 6-week OA study of rofecoxib vs placebo." | 5.10 | Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. ( Bolognese, JA; Ehrich, EW; Schnitzer, TJ, 2003) |
| "An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment." | 5.10 | Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003) |
| "The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect." | 5.10 | A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003) |
| "Thirty-seven percent of patients receiving placebo and 42% of patients receiving rofecoxib had significant pain (5 or greater on the visual analog pain scale)." | 5.10 | A randomized double-blind prospective study evaluating patient tolerance of transrectal ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib. ( Hamawy, KJ; Moinzadeh, A; Mourtzinos, A; Triaca, V, 2003) |
| " In the dental pain study, total pain relief (TOTPAR) over the 6 hours after dosing was similar between 50 mg and 500 mg rofecoxib and 400 mg ibuprofen (P > ." | 5.09 | Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. ( Dallob, A; De Lepeleire, I; De Schepper, P; Ehrich, EW; Gertz, BJ; Mehlisch, DR; Porras, A; Riendeau, D; Seibold, JR; Van Hecken, A; Wittreich, J; Yuan, W, 1999) |
| "Rofecoxib effectively treated primary dysmenorrhea, and cyclooxygenase-2-derived prostanoids play a role in the pathophysiology of primary dysmenorrhea." | 5.09 | Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. ( Cantu, N; Daniels, SE; Kotey, P; Morrison, BW; Seidenberg, B, 1999) |
| "Thirteen patients with osteoid osteoma were enrolled in a prospective trial to test whether rofecoxib, a selective cyclooxygenase-2 inhibitor, is as effective for pain control as acetylsalicylic acid." | 5.09 | Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma. ( Bottner, F; Grethen, C; Lindner, N; Roedl, R; Winkelmann, W; Wortler, K, 2001) |
| "To assess the efficiency of paracetamol, indicated in first instance for light-to-moderate pain from hip and knee arthrosis, against rofecoxib, the COX-2 inhibitor most commonly used in Spain." | 4.82 | [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. ( Lizán Tudela, L; Magaz Marqués, S; Riesgo Bucher, Y; Varela Moreno, C, 2004) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "Although the published literature is limited, the data indicate that rofecoxib is an effective analgesic agent for the painful conditions in which it has been studied." | 4.81 | Rofecoxib: clinical pharmacology and clinical experience. ( Weaver, AL, 2001) |
| "This study showed that TS has anti-visceral pain properties comparable with those of rofecoxib (a cyclooxygenase-2 inhibitor) and diclofenac, which suggests promise for the treatment of intractable visceral pain in humans." | 3.81 | Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test. ( Chan, TF; Hsu, HK; Hwang, SL; Lee, KS; Lieu, AS; Lin, CL; Su, YF; Yang, YC, 2015) |
| "The dose-response relation of S-methylisothiourea, rofecoxib, mefenamic acid, and their combination was studied in the late phase of formalin-induced pain in mice over the time spent in licking the hindpaw after formalin injection." | 3.74 | The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study. ( Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2008) |
| "Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor approved for the treatment of pain and arthritis in adults." | 3.72 | Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. ( Aranda, JV; Edwards, DJ; Frattarelli, DA; Haritos, D; Prescilla, RP, 2004) |
| " Five days before admission, rofecoxib, a new selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID), was added for leg pain." | 3.71 | Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. ( Armoni, M; Bukish, N; Derazon, H; Hay, E; Katz, L; Kruglyakov, I, 2002) |
| "To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement." | 3.71 | Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. ( Bolognese, J; Detora, LM; Ehrich, EW; Krupa, D; Sperling, RS, 2001) |
| "Pretreatment with Rofecoxib significantly reduced post-SWL pain from 5." | 2.74 | Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib. ( Erturk, E; Greene, TD; Joseph, JV, 2009) |
| "Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment." | 2.73 | Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. ( Dionne, RA; Hamza, M; Ramsay, ES; Wahl, SM; Wang, XM; Wu, TX, 2007) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| "Rofecoxib is a specific inhibitor of cyclooxygenase-2 (COX-2), thereby inhibiting prostanoid synthesis in cells that express COX-2, including inflammatory cells." | 2.41 | Rofecoxib. ( Furst, DE; Hillson, JL, 2000) |
| "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day." | 2.41 | Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001) |
| " During repeated dosage with the specific COX-2 inhibitors, the 24 hour urinary excretion of sodium is only inhibited for the first day of treatment while the excretion of sodium is still decreased over the first 3 hours after the individual doses." | 2.41 | Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). ( Day, RO; Graham, GG; Graham, RI, 2002) |
| "Rofecoxib was used for eight acute haemarthrosis, four target joints, seven cases of synovitis and 12 episodes of pain." | 1.33 | Rofecoxib as adjunctive therapy for haemophilic arthropathy. ( Nugent, DJ; Rattray, B; Young, G, 2005) |
| "Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis." | 1.32 | [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003) |
| "Acute inflammation was induced by sub-plantar injection of carrageenan (1%) in the rat hind paw." | 1.31 | Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR; El-Batran, S; El-Shenawy, SM, 2002) |
Research
Studies (76)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.58) | 18.2507 |
| 2000's | 67 (88.16) | 29.6817 |
| 2010's | 4 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Black, WC | 1 |
| Brideau, C | 1 |
| Chan, CC | 1 |
| Charleson, S | 1 |
| Cromlish, W | 1 |
| Gordon, R | 1 |
| Grimm, EL | 1 |
| Hughes, G | 1 |
| Leger, S | 1 |
| Li, CS | 1 |
| Riendeau, D | 2 |
| Thérien, M | 1 |
| Wang, Z | 2 |
| Xu, LJ | 1 |
| Prasit, P | 1 |
| Giblin, GM | 1 |
| Billinton, A | 1 |
| Briggs, M | 1 |
| Brown, AJ | 1 |
| Chessell, IP | 2 |
| Clayton, NM | 1 |
| Eatherton, AJ | 1 |
| Goldsmith, P | 1 |
| Haslam, C | 1 |
| Johnson, MR | 1 |
| Mitchell, WL | 1 |
| Naylor, A | 1 |
| Perboni, A | 1 |
| Slingsby, BP | 1 |
| Wilson, AW | 2 |
| Blouin, M | 1 |
| Han, Y | 2 |
| Burch, J | 1 |
| Farand, J | 1 |
| Mellon, C | 1 |
| Gaudreault, M | 1 |
| Wrona, M | 2 |
| Lévesque, JF | 2 |
| Denis, D | 2 |
| Mathieu, MC | 2 |
| Stocco, R | 2 |
| Vigneault, E | 1 |
| Therien, A | 1 |
| Clark, P | 1 |
| Rowland, S | 2 |
| Xu, D | 2 |
| O'Neill, G | 1 |
| Ducharme, Y | 2 |
| Friesen, R | 2 |
| Colucci, J | 1 |
| Boyd, M | 1 |
| Berthelette, C | 1 |
| Chiasson, JF | 1 |
| Therien, AG | 1 |
| Clarke, P | 1 |
| Werner, S | 1 |
| Mesch, S | 1 |
| Hillig, RC | 1 |
| Ter Laak, A | 1 |
| Klint, J | 1 |
| Neagoe, I | 1 |
| Laux-Biehlmann, A | 1 |
| Dahllöf, H | 1 |
| Bräuer, N | 1 |
| Puetter, V | 1 |
| Nubbemeyer, R | 1 |
| Schulz, S | 1 |
| Bairlein, M | 1 |
| Zollner, TM | 1 |
| Steinmeyer, A | 1 |
| Su, YF | 1 |
| Yang, YC | 1 |
| Hsu, HK | 1 |
| Hwang, SL | 1 |
| Lee, KS | 1 |
| Lieu, AS | 1 |
| Chan, TF | 1 |
| Lin, CL | 1 |
| Greene, TD | 1 |
| Joseph, JV | 1 |
| Erturk, E | 1 |
| Hay, E | 1 |
| Derazon, H | 1 |
| Bukish, N | 1 |
| Katz, L | 1 |
| Kruglyakov, I | 1 |
| Armoni, M | 1 |
| El-Shenawy, SM | 1 |
| Abdel-Salam, OM | 1 |
| Baiuomy, AR | 1 |
| El-Batran, S | 1 |
| Arbid, MS | 1 |
| Bolognese, JA | 2 |
| Schnitzer, TJ | 3 |
| Ehrich, EW | 4 |
| Collantes-Estevez, E | 1 |
| Fernandez-Perez, C | 1 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Burian, M | 1 |
| Geisslinger, G | 1 |
| Moinzadeh, A | 1 |
| Mourtzinos, A | 1 |
| Triaca, V | 1 |
| Hamawy, KJ | 1 |
| Déciga-Campos, M | 1 |
| López-Muñoz, FJ | 2 |
| Emkey, R | 1 |
| Rosenthal, N | 1 |
| Wu, SC | 1 |
| Jordan, D | 1 |
| Kamin, M | 1 |
| Morović-Vergles, J | 1 |
| Dudhgaonkar, SP | 1 |
| Kumar, D | 2 |
| Naik, A | 1 |
| Devi, AR | 1 |
| Bawankule, DU | 1 |
| Tandan, SK | 2 |
| Chang, DJ | 1 |
| Desjardins, PJ | 1 |
| Bird, SR | 1 |
| Black, P | 1 |
| Chen, E | 1 |
| Petruschke, RA | 2 |
| Geba, GP | 2 |
| White, WB | 1 |
| Jayr, C | 2 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Prescilla, RP | 1 |
| Frattarelli, DA | 1 |
| Haritos, D | 1 |
| Aranda, JV | 1 |
| Edwards, DJ | 1 |
| Brune, K | 2 |
| Zacher, J | 1 |
| Gallagher, RM | 1 |
| Lizán Tudela, L | 1 |
| Magaz Marqués, S | 1 |
| Varela Moreno, C | 1 |
| Riesgo Bucher, Y | 1 |
| Spake, A | 1 |
| Flynn, J | 1 |
| Torg, J | 1 |
| Mamdani, M | 1 |
| Rattray, B | 1 |
| Nugent, DJ | 1 |
| Young, G | 1 |
| Weaver, AL | 2 |
| Polis, AB | 1 |
| Moore, RA | 1 |
| Edwards, JE | 1 |
| McQuay, HJ | 1 |
| Poomtavorn, Y | 1 |
| Phupong, V | 1 |
| Medhurst, SJ | 1 |
| Dixon, CI | 1 |
| Bontoft, NC | 1 |
| Winyard, LA | 1 |
| Brackenborough, KT | 1 |
| De Alba, J | 1 |
| Clarke, CJ | 1 |
| Gunthorpe, MJ | 1 |
| Hicks, GA | 1 |
| Bountra, C | 1 |
| McQueen, DS | 1 |
| Loram, LC | 1 |
| Mitchell, D | 1 |
| Fuller, A | 1 |
| Kumar, VL | 1 |
| Roy, S | 1 |
| Sehgal, R | 1 |
| Padhy, BM | 1 |
| Wang, XM | 1 |
| Wu, TX | 1 |
| Hamza, M | 1 |
| Ramsay, ES | 1 |
| Wahl, SM | 1 |
| Dionne, RA | 1 |
| Underwood, A | 1 |
| Murase, A | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Tonai-Kachi, H | 1 |
| Nakao, K | 1 |
| Takada, J | 1 |
| Bhat, AS | 1 |
| Krishna, V | 1 |
| Prakash, VR | 1 |
| Dallob, A | 1 |
| De Lepeleire, I | 1 |
| Van Hecken, A | 1 |
| Yuan, W | 1 |
| Porras, A | 1 |
| Wittreich, J | 1 |
| Seibold, JR | 1 |
| De Schepper, P | 1 |
| Mehlisch, DR | 1 |
| Gertz, BJ | 1 |
| Morrison, BW | 1 |
| Daniels, SE | 1 |
| Kotey, P | 1 |
| Cantu, N | 1 |
| Seidenberg, B | 1 |
| Rodgers, E | 1 |
| Miller, JL | 1 |
| Hinz, B | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 1 |
| Rask-Madsen, J | 1 |
| Cannon, GW | 1 |
| Breedveld, FC | 1 |
| Hillson, JL | 1 |
| Furst, DE | 1 |
| Stichtenoth, DO | 1 |
| Frölich, JC | 1 |
| Stienburg, KL | 1 |
| Matheson, AJ | 1 |
| Figgitt, DP | 1 |
| Comarow, A | 1 |
| Adler, J | 1 |
| Nakamura, H | 1 |
| Kessenich, CR | 1 |
| Detora, LM | 1 |
| Krupa, D | 1 |
| Bolognese, J | 1 |
| Sperling, RS | 1 |
| Bottner, F | 1 |
| Roedl, R | 1 |
| Wortler, K | 1 |
| Grethen, C | 1 |
| Winkelmann, W | 1 |
| Lindner, N | 1 |
| Sirakov, M | 1 |
| Martínez, RV | 1 |
| Reval, M | 1 |
| Campos, MD | 1 |
| Terrón, JA | 1 |
| Domínguez, R | 1 |
| Graham, GG | 1 |
| Graham, RI | 1 |
| Day, RO | 1 |
| Lundmark, J | 1 |
| Gunnarsson, T | 1 |
| Bengtsson, F | 1 |
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain[NCT00092313] | Phase 3 | 271 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Efficacy for Acute Pain Alleviation of 50 mg Diclofenac 1 Hour Prior to Endometrial Sampling in Cases of Abnormal Uterine Bleeding[NCT01762306] | 90 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | |||
| The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee[NCT00752765] | 30 participants (Anticipated) | Observational | 2008-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
17 reviews available for rofecoxib and Ache
| Article | Year |
|---|---|
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
[Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Costs and Cost Analysis; Cyclooxygenase 2; Cyclooxygenase 2 | 2004 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; H | 2004 |
Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Ibuprofen; Lact | 2005 |
Treating pain with COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Drug Inte | 1999 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Efficacy of cyclooxygenase-2-specific inhibitors.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge | 2001 |
Rofecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2000 |
[Therapy with preferential and specific COX-2 inhibitors].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cycl | 2001 |
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tri | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Rofecoxib: clinical pharmacology and clinical experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Osteoarthritis; Pa | 2001 |
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr | 2001 |
COX-2 inhibitors: no pain, no heart gain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenas | 2001 |
[VIOXX--a new world without pain].
Topics: Adult; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Lactones; Pain; Sulfones | 2001 |
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
Topics: Acetaminophen; Analgesia; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase | 2002 |
Trials
16 trials available for rofecoxib and Ache
| Article | Year |
|---|---|
Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib.
Topics: Cyclooxygenase 2 Inhibitors; Female; Humans; Lactones; Lithotripsy; Male; Middle Aged; Multivariate | 2009 |
Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Endpoint Determination; Humans; Lacton | 2003 |
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Health Status; Humans; Lactones; Logistic Models | 2003 |
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; M | 2003 |
A randomized double-blind prospective study evaluating patient tolerance of transrectal ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy, Needle; Double-Blind Method; Humans; Lactones | 2003 |
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; | 2004 |
Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial.
Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Analgesics; Dose-Response Relationship, Drug; Doubl | 2004 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response | 2005 |
Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage.
Topics: Adult; Cyclooxygenase 2 Inhibitors; Dilatation and Curettage; Double-Blind Method; Female; Humans; L | 2005 |
Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers.
Topics: Adult; Creatine Kinase; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Exerci | 2005 |
Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Cytokines; | 2007 |
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Topics: Adult; Analgesics, Non-Narcotic; Animals; CHO Cells; Cricetinae; Cyclooxygenase Inhibitors; Dinopros | 1999 |
Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial.
Topics: Adolescent; Adult; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Lactones; Pain; Sulfones | 1999 |
Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
Topics: Analgesics; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans | 2001 |
Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bone Neoplasms; Cyclooxygenase | 2001 |
Other Studies
43 other studies available for rofecoxib and Ache
| Article | Year |
|---|---|
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi | 2003 |
Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Topics: Aminopyridines; Animals; Aza Compounds; Brain; Cell Line; CHO Cells; Chronic Disease; Cricetinae; Cr | 2009 |
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.
Topics: Analgesics; Animals; Benzoates; Cyclopropanes; Half-Life; Humans; Magnetic Resonance Spectroscopy; M | 2010 |
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.
Topics: Animals; Arthritis; Benzoates; Cells, Cultured; Dogs; Drug Discovery; Drug Stability; Hepatocytes; H | 2010 |
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor
Topics: Acetamides; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochr | 2019 |
Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cycloox | 2015 |
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Diet; Drug Interactions; | 2002 |
[No chance for pain. Rofecoxib eases not only tooth extraction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; La | 2002 |
Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat.
Topics: Administration, Topical; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Information on preoperative analgesia. Acute pain therapy with rofecoxib].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Pain; Preoperative Care; S | 2003 |
[Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors | 2003 |
[Meta-analysis on acute pain. Rofecoxib helped three quarters of patients].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretati | 2003 |
Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Cyclic GMP; Cyclooxygenase 2; Cyclooxyge | 2003 |
[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibi | 2003 |
Interaction of inducible nitric oxide synthase and cyclooxygenase-2 inhibitors in formalin-induced nociception in mice.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Rel | 2004 |
[Selective COX-2 inhibitors--strong medicine for pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans | 2004 |
Hypertension associated with therapies to treat arthritis and pain.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 2004 |
[General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inh | 2004 |
Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
Topics: Administration, Oral; Adolescent; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Anti-Inflammatory A | 2004 |
[Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
Topics: Colonic Polyps; Cyclooxygenase Inhibitors; Germany; Humans; Lactones; Long-Term Care; Myocardial Inf | 2004 |
Balancing risks and benefits in pain medicine: wither Vioxx.
Topics: Consumer Product Safety; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans | 2004 |
The price of pain.
Topics: Cyclooxygenase Inhibitors; Humans; Lactones; Pain; Sulfones; United States | 2005 |
Treating pain after Vioxx. Should you switch to another COX-2, a traditional non-steroidal anti-inflammatory, or acetaminophen.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inh | 2005 |
Easing arthritis pain in the post-Vioxx era.
Topics: Arthritis; Cyclooxygenase Inhibitors; Humans; Lactones; Pain; Sulfones | 2005 |
Vioxx and Merck: a preventable situation?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Industry; Humans; Hypertensi | 2005 |
The changing landscape for COX-2 inhibitors: a summary of recent events.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Human | 2005 |
Rofecoxib as adjunctive therapy for haemophilic arthropathy.
Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Adult; Anti-Inflammatory A | 2005 |
An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models.
Topics: Animals; Arthritis; Chronic Disease; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Freund's A | 2006 |
A comparative study on the efficacy of rofecoxib in monoarticular arthritis induced by latex of Calotropis procera and Freund's complete adjuvant.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Calotropis; Cyclooxygenase 2 Inhibitors; Fem | 2006 |
Life after Vioxx.
Topics: Arthritis; Cyclooxygenase 2 Inhibitors; Dietary Supplements; Drug and Narcotic Control; Humans; Infl | 2005 |
Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents; Benzamides; Benzoates; Cell Lin | 2008 |
The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study.
Topics: Animals; Behavior, Animal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2008 |
Rofecoxib for osteoarthritis and pain.
Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit | 1999 |
Second selective COX-2 inhibitor receives marketing approval.
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 1999 |
[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2000 |
Rofecoxib (Vioxx): a year in review.
Topics: Adverse Drug Reaction Reporting Systems; Canada; Cardiovascular Diseases; Enzyme Inhibitors; Humans; | 2001 |
Pain relief at a price. A blow to the heart?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; | 2001 |
Arthritis: what it is, why you get it and how to stop the pain.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy | 2001 |
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; D | 2001 |
[Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain].
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents | 2002 |
Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain.
Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Inflammation; Lactones | 2002 |
[New indication for selective COX-2 inhibitors. Now also approve for acute pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug A | 2002 |
A possible interaction between lithium and rofecoxib.
Topics: Aged; Creatinine; Depression; Drug Interactions; Humans; Lactones; Lithium; Male; Pain; Sulfones | 2002 |